A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

Keytruda plus Lenvima demonstrates durable 5-year survival benefit versus chemotherapy for patients with advanced endometrial carcinoma following one prior platinum-based regimen ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

Merck (MRK), known as MSD outside of the United States and Canada, announced results demonstrating KEYTRUDA plus Padcev reduced the risk of event-free survival, EFS, events by 60% and reduced the risk ...

Merck (MRK) and Eisai (ESAIY) announced long-term follow-up data continued to show durable benefit of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA ® (pembrolizumab), Merck’s ...

The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...